Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Invitae | RCV001233433 | SCV001406026 | likely pathogenic | Ornithine carbamoyltransferase deficiency | 2023-09-08 | criteria provided, single submitter | clinical testing | This sequence change replaces serine, which is neutral and polar, with proline, which is neutral and non-polar, at codon 96 of the OTC protein (p.Ser96Pro). This variant is present in population databases (rs184053962, gnomAD 0.008%). This missense change has been observed in individual(s) with clinical features of OTC deficiency (PMID: 30175132). ClinVar contains an entry for this variant (Variation ID: 959988). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt OTC protein function. This variant disrupts the p.Ser96 amino acid residue in OTC. Other variant(s) that disrupt this residue have been observed in individuals with OTC-related conditions (PMID: 17334707), which suggests that this may be a clinically significant amino acid residue. In summary, the currently available evidence indicates that the variant is pathogenic, but additional data are needed to prove that conclusively. Therefore, this variant has been classified as Likely Pathogenic. |
Revvity Omics, |
RCV001233433 | SCV004235694 | uncertain significance | Ornithine carbamoyltransferase deficiency | 2023-05-04 | criteria provided, single submitter | clinical testing |